“Genetic engineering startup Colossal Biosciences has added the South Island giant moa — a powerful, long-necked species that stood 10 feet (3 meters) tall and may have kicked in self-defense — to a fast-expanding list of animals it wants to resurrect by genetically modifying their closest living relatives.

The company stirred widespread excitement, as well as controversy, when it announced the birth of what it described as three dire wolf pups in April. Colossal scientists said they had resurrected the canine predator last seen 10,000 years ago by using ancient DNA, cloning and gene-editing technology to alter the genetic make-up of the gray wolf, in a process the company calls de-extinction. Similar efforts to bring back the woolly mammoth, the dodo and the thylacine, better known as the Tasmanian tiger, are also underway. 

To restore the moa, Colossal Biosciences announced Tuesday it would collaborate with New Zealand’s Ngāi Tahu Research Centre, an institution based at the University of Canterbury in Christchurch, New Zealand, that was founded to support the Ngāi Tahu, the main Māori tribe of the southern region of New Zealand.

The project would initially involve recovering and analyzing ancient DNA from nine moa species to understand how the giant moa (Dinornis robustus) differed from living and extinct relatives in order to decode its unique genetic makeup, according to a company statement.”

From CNN.

“Teeth from an elderly man who lived around the time that the earliest pyramids were built have yielded the first full human genome sequence from ancient Egypt.

The remains are 4,800 to 4,500 years old, overlapping with a period in Egyptian history known as the Old Kingdom or the Age of Pyramids. They harbour signs of ancestry similar to that of other ancient North Africans, as well as of people from the Middle East, researchers report today in Nature.”

From Nature.

“From 1 July, researchers funded by the US National Institutes of Health (NIH) will be required to make their scientific papers available to read for free as soon as they are published in a peer-reviewed journal. That’s according to the agency’s latest public-access policy, aimed at making federally funded research accessible to taxpayers.”

“In a laboratory outside Cambridge sits a remarkable ‘biological computer’. Its 200,000 human brain cells, grown in the lab, lie on silicon circuitry that communicates their synchronised electrical activity on a screen to the outside world.

The CL1 device, about the size of two shoe boxes, was developed by Australian start-up Cortical Labs with the UK’s bit.bio, in a bid to create ‘synthetic biological intelligence’ — a new form of computing that could offer opportunities beyond conventional electronics and other developing technologies such as quantum…

Early applications of CL1 are in neuroscience and pharmaceutical research, discovering how different chemicals and drug candidates affect the brain cells’ information processing.”

From Nature.

“Today [6/25/25], we introduce AlphaGenome, a new artificial intelligence (AI) tool that more comprehensively and accurately predicts how single variants or mutations in human DNA sequences impact a wide range of biological processes regulating genes…

Our AlphaGenome model takes a long DNA sequence as input — up to 1 million letters, also known as base-pairs — and predicts thousands of molecular properties characterising its regulatory activity. It can also score the effects of genetic variants or mutations by comparing predictions of mutated sequences with unmutated ones.

Predicted properties include where genes start and where they end in different cell types and tissues, where they get spliced, the amount of RNA being produced, and also which DNA bases are accessible, close to one another, or bound by certain proteins.”

From DeepMind.